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Abstract
Background: Guidelines now recommend routine assessment of global coronary heart disease (CHD)
risk scores. We performed a systematic review to assess whether global CHD risk scores result in clinical
benefits or harms.
Methods: We searched MEDLINE (1966 through June 13, 2007) for articles relevant to our review. Using
predefined inclusion and exclusion criteria, we included studies of any design that provided physicians with
global risk scores or allowed them to calculate scores themselves, and then measured clinical benefits and/
or harms. Two reviewers reviewed potentially relevant studies for inclusion and resolved disagreement by
consensus. Data from each article was then abstracted into an evidence table by one reviewer and the
quality of evidence was assessed independently by two reviewers.
Results: 11 studies met criteria for inclusion in our review. Six studies addressed clinical benefits and 5
addressed clinical harms. Six studies were rated as "fair" quality and the others were deemed
"methodologically limited". Two fair quality studies showed that physician knowledge of global CHD risk
is associated with increased prescription of cardiovascular drugs in high risk (but not all) patients. Two
additional fair quality studies showed no effect on their primary outcomes, but one was underpowered
and the other focused on prescribing of lifestyle changes, rather than drugs whose prescribing might be
expected to be targeted by risk level. One of these aforementioned studies showed improved blood
pressure in high-risk patients, but no improvement in the proportion of patients at high risk, perhaps due
to the high proportion of participants with baseline risks significantly exceeding the risk threshold. Two
fair quality studies found no evidence of harm from patient knowledge of global risk scores when they were
accompanied by counseling, and optional or scheduled follow-up. Other studies were too
methodologically limited to draw conclusions.
Conclusion: Our review provides preliminary evidence that physicians' knowledge of global CHD risk
scores may translate into modestly increased prescribing of cardiovascular drugs and modest short-term
reductions in CHD risk factors without clinical harm. Whether these results are replicable, and translate
across other practice settings or into improved long-term CHD outcomes remains to be seen.
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Despite numerous guidelines and abundant evidence
regarding the efficacy of interventions to prevent cardio-
vascular disease (CVD), the majority of people with CVD
risk factors do not have them under adequate control [1-
5]. One contributing factor is that many clinicians do not
accurately estimate a patient's risk of CVD [6-10]. This
may lead to under use of effective therapies and, in some
cases, excess harms.
Several major guidelines now advocate routine assess-
ment of cardiovascular risk using coronary heart disease
(CHD) risk scores as a means to aid clinicians in decision-
making [11-13]. The major benefits in using global CHD
risk scores are improved prediction of CHD outcomes
[14] and improved physician knowledge of a patient's
actual risk. These may in turn result in earlier identifica-
tion of high-risk patients who require immediate atten-
tion, more appropriate allocation of therapies to those
most likely to benefit, and improved intermediate and
long term outcomes for patients [15,16]. To the extent
that the risk information is communicated to patients,
global CHD risk scores may also improve patient under-
standing of their risk for CVD and the rationale for any
proposed treatments, and patient motivation to adhere to
prescribed risk-reducing interventions [13].
Despite clear-cut recommendations for the use of global
CHD risk scores, relatively little is known about whether
use of such assessments actually translates into improved
clinical outcomes [17]. In particular, little is known about
how knowledge of a patient's calculated 10-year CHD risk
affects physicians' actions (i.e. prescribing or adherence to
guidelines) or whether these actions translate into
improved outcomes for patients through improved
acceptance of or adherence to CHD risk-reducing thera-
pies. We undertook this systematic review to summarize
available evidence about the effects of physician knowl-
edge of global CHD risk.
Methods
Questions to be reviewed
The primary question to be addressed by this systematic
review is: Does physician knowledge of a global CHD risk
scores (as opposed to either simple risk factor counting or
no formal assessment of risk) translate into clinical bene-
fits? For the purposes of this review, we defined clinical
benefits as either (1) improved physician adherence with
evidence-based guidelines for the primary prevention of
CVD, (2) increased appropriate prescribing of risk-modi-
fying therapies, (3) increased patient acceptance of or
adherence to therapies targeted at the primary prevention
of CVD, (4) improved control of patient CVD risk factors
(e.g. blood pressure, cholesterol), or (5) a reduction in
CVD events.
Our secondary question was whether there are any harms
(from the patient perspective) associated with screening
using global risk scores. Since harms can be difficult to
predict, we chose to broadly define clinical harms as any
adverse physical or psychosocial outcome that correlated
with screening.
Search strategy
We searched MEDLINE (1966 – June 13, 2007) using
MeSH terms in two distinct search strategies (see Addi-
tional file 1). Each search was limited to studies in
humans and to the English language literature. To aug-
ment our findings, we additionally performed related arti-
cles searches of included articles in MEDLINE and hand-
searched the bibliographies of included articles and our
files looking for additional articles on the effects of CHD
risk calculation on clinical outcomes.
Study inclusion criteria
In our search for articles about the benefits of physician
knowledge of global CHD risk scores, we included studies
of any design that met the following criteria: (1) study
population consisted of adults (>18 years old) with no
prior history of CVD; (2) global CHD risk calculation was
specified as the primary study intervention; (3) there was
clear documentation of the calculation of a global CHD
risk score by a physician or other health care provider as
part of an individual patient encounter (Note: question-
naire-based studies were considered acceptable as long as
they were designed to simulate clinical encounters with
patients); and (4) one or more of the following endpoints
was used: (i) rates of prescribing for aspirin, anti-hyper-
tensive medication, lipid-lowering medication, smoking
cessation therapies, or diet and exercise; (ii) physician
compliance with guidelines for CVD prevention; (iii)
patient adherence with therapy; (iv) change in patient
blood pressure, cholesterol levels, aspirin use, smoking
cessation, diet or exercise; or (v) rate of CVD events
(defined here as new onset stroke/transient ischemic
attack, myocardial infarction, acute coronary syndrome,
stable angina, peripheral vascular disease, carotid artery
disease, or cardiac death).
In our search for articles about the potential harms associ-
ated with physician knowledge of global CHD risk scores,
we included studies that met the following criteria: (1)
study population consisted of adults (>18 years old) with
no prior history of CVD; (2) assessment of the adverse
effect of global CHD risk calculation was specified as the
primary study goal; and (3) one or more of the following
patient-specific endpoints was used: (i) general health
and wellbeing, (ii) anxiety or worry, (iii) depression, or
(iv) motivation to lower CHD risk.Page 2 of 14
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Framingham-derived estimates preferable, however other
scoring systems were acceptable as long as they presented
risk in a comparable fashion (i.e. as an absolute risk esti-
mate or in terms of risk categories – low, intermediate,
high). Additionally, in order to be included, studies had
to provide enough information so that it was possible to
determine the method of global risk calculation as well as
the manner in which the risk assessment was used in the
clinical encounter.
Study exclusion criteria
In our search for articles about the benefits of physician
knowledge of global CHD risk scores, we excluded studies
for the following reasons: (1) studies were unrelated to
global CHD risk calculation; (2) they calculated the risk
scores for the secondary prevention of CHD risk; (3) they
answered the wrong question about CHD risk scores (e.g.
they were related to development and validation of risk
scores; the conceptual understanding of risk scores; the
accuracy of risk perception; the accuracy of systems to cal-
culate CHD risk; or the acceptability of decision aids
including CHD risk); (4) they used risk scores for the
wrong use (e.g. as part of the eligibility criteria or end-
points of a study, but not as information for physicians);
(5) they were about the benefits of CHD risk scores, but
did not have a quantitative experimental design (e.g.
reviews, editorials, qualitative studies, methods papers);
(6) they used a non-controlled experimental design (e.g.
pre-post designs); (7) they focused on the effects of
patient knowledge of CHD risk scores; or (8) they admin-
istered global risk as part of a mixed intervention without
the ability to determine the independent effect of the risk
score.
In our search for articles about the potential harms associ-
ated with physician knowledge of global CHD risk scores,
we excluded articles because (1) they were unrelated to
the harms of CHD risk disclosure; (2) they were related to
CHD risk disclosure, but were not about disclosing global
CHD risk; (3) they answered the wrong question (e.g. the
effects of disclosure in secondary prevention); or (4) they
didn't have an experimental design.
Data extraction strategy
Two reviewers (EC, SS) independently reviewed titles,
abstracts, and, if necessary, full articles to determine inclu-
sion. Disagreements were resolved by discussion. Once
consensus about article inclusion was achieved, one
reviewer (EC or SS) abstracted information about study
features into tables for analysis and two reviewers inde-
pendently assessed study quality.
Assessment of study quality
We assessed study quality using criteria adapted from the
U.S. Preventive Services Task Force [18]. Under these cri-
teria both research design and internal validity are taken
into account when assessing the quality of an individual
study.
The study grade for internal validity was based on fulfill-
ment of the following criteria: (1) creation and mainte-
nance of comparable study groups; (2) valid and reliable
measurement that is applied equally to both study groups;
(3) provision of a clear definition of the intervention; and
(4) performance of appropriate statistical analysis, includ-
ing appropriate control for confounding and accounting
for cluster randomized design if necessary. For each study,
we graded each criterion as good, fair, or poor. We then
converted our quality ratings for each item into numeric
values (0 = poor, 1 = fair, and 2 = good) and created a com-
posite rating for each study. We gave each item equal
weight and excluded items we judged to be not applicable
based on study design. We totaled and averaged scores for
each evaluator and then averaged scores from the two
evaluators, giving a final score ranging from 0 to 2. We
based our final quality grades on averaged scores accord-
ing to the following scale: a mean score ≥ 1.5 was consid-
ered good quality; a mean score of 1.0 to 1.49 was
considered fair quality; and a mean score < 1.0 was con-
sidered to denote a study with significant methodological
limitations.
In order to account for study information which may have
been collected but which was not included in the pub-
lished article (due to space limitations, etc), we requested
further information from the contact authors via email
when we had specific questions about information that
was missing. We sent reminders to contacted authors who
did not respond within one month after our initial con-
tact.
Results
Search results
We summarize the results of our two literature searches in
Figures 1 and 2. In our search for articles about clinical
benefits, we identified 6 studies for inclusion in our
review. We identified three through our primary literature
search, one through hand searching, and two through
related articles searches.
In our search for articles about the harms, we identified 5
articles for inclusion. We identified three articles through
our primary search and two through related articles
searches.Page 3 of 14
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Literature search results for benefits of physician knowledge of global CHD risk scoresFigure 1
Literature search results for benefits of physician knowledge of global CHD risk scores. * Note: Several articles 
that may be of interest to readers were not included from related articles searches because they: did not have an experimental 
design [64-69], had no comparison group [70-79], had patients rather than physicians calculate risk scores [80-82], or had 
mixed interventions [83-89].
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A total of eleven studies were included in our review: six
addressed whether physician knowledge of a global risk
score translates into improved clinical outcomes (see
Additional file 2) [19-24]; five addressed whether global
risk scores are associated with harm (see Additional file 3)
[25-29]. All included studies were published after 1995.
Of the six studies that addressed clinical benefit, three
were cluster randomized controlled trials, two were tradi-
tional randomized controlled trials, and one was a cross-
sectional study. Five took place in actual clinical settings
[20-24], whereas a sixth study queried physicians using
hypothetical patient scenarios[19]. Of those in actual clin-
ical settings, four [20,21,23,24] took place in a general
practice population and one [22] was conducted in a dia-
betes referral clinic. All six studies used some form of a
Framingham-derived risk score [19-24]. In three studies,
risk scores were provided to the physician [21-23]. The
number of patients and, more importantly, physicians
included in each study varied widely, with the study by
Hall being the smallest (6 physicians, 323 patients) and
the study by Lowensteyn being the largest (253 physi-
cians, 958 patients). As can be seen in Additional file 2,
Literature search results for harms of physician knowledge of global CHD risk scoresFigure 2
Literature search results for harms of physician knowledge of global CHD risk scores. *Note: Two articles that 
may be of interest to readers were not included from related articles searches because they reported on the harms of CVD 
screening (but not presentation of global CHD risk) [105, 106].
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widely. No studies addressed actual CVD event rates or the
effect of risk scores on patient adherence.
Of the five studies that addressed potential harms, two
were randomized controlled trials, two were cohort stud-
ies, and one was a nested cross-sectional study. All took
place in general practice populations (Additional file 3).
Three studies used risk scores derived from epidemiologic
databases other than Framingham (e.g the Northwick
Park Heart Study [26], the British Regional Heart Study
and Dundee risk score [25], and the Norwegian Infarction
Score [29]). Two studies used a risk score that was a com-
posite of data from Framingham, the Pooling Project, and
the NHBLI working group on Arteriosclerosis [27,28,30].
In all studies, the risk scores were presented in a categori-
cal format (low, intermediate, high) similar to Framing-
ham scores.
Study quality
Despite obtaining additional information from 10 of 11
authors [19-23,25-29], study quality ratings ranged from
"methodologically limited" to "fair" (see Additional file
4). Across all of the studies a major limitation in deter-
mining both the internal validity of each study was a lack
of detailed information about the study procedures and
the baseline characteristics of both the physicians and the
patients. This created difficulty in assessing the adequacy
of randomization, selection bias, and confounding.
The benefits of risk calculation
Changes in physicians' prescribing habits
Four fair quality studies [20,22-24] examined the effects
of CHD risk calculation on physicians' prescribing habits.
Although only the Hall, Jacobsen, and van Steenkiste
studies considered prescribing habits a primary outcome,
the study by Montgomery provides important evidence
due to its larger sample of physicians and its appropriate
accounting for the effects of clustering.
In the study by Hall and colleagues, six diabetologists saw
323 diabetic patients without known CHD who were
pseudo-randomized (e.g. alternately allocated) to an
experimental group (5-year CHD risk scores (New Zea-
land risk score) placed on the front of the chart prior to
visit) or to a usual care group (no risk information pro-
vided). Outcomes measured post-visit included a docu-
mented change in treatment of diabetes, prescription rates
for lipid lowering or antihypertensive drugs, and referrals
to a dietician. Overall, documentation of a risk score did
not have an effect on physician prescribing habits; how-
ever, in an a priori subgroup analysis of high risk patients
(5-year CHD risk > 20%; encompassing 52% of the
patients in the study), there was a trend toward more pre-
scribing of a lipid lowering and anti-hypertensive drugs
when risk was documented on the chart (23% vs. 10% for
antihypertensive agents and 20% vs. 9% for lipid-lower-
ing agents). Additionally, after adjusting for the level of
risk, the difference in prescribing of lipid lowering and
anti-hypertensive drugs between the intervention and
control groups was significant (Mantel Hansel chi square,
p < 0.02). There was no difference in prescribing of diabe-
tes treatment or referrals to dieticians.
The study by Montgomery and colleagues supports these
findings. In this study, 27 practices (including 74 physi-
cians and 11 nurses) were randomized to receive one of
three interventions: (1) a CHD risk chart (New Zealand
risk chart), (2) a CHD risk chart plus a computer-based
clinical decision support system that calculated risk using
New Zealand chart principles, or (3) usual care. Out-
comes, including the proportion of patients at high risk,
physician prescribing habits, and blood pressure, were
measured at 12-month follow-up on 614 patients, 86% of
whom were at high risk (mean 5 year CHD risk 18.5%).
After adjustment for practice site (n = 27) and for baseline
CHD risk, a similar proportion of patients in all three
groups were still at high risk. Physicians in the chart only
group, however, had two times the odds of prescribing
cardiovascular drugs as physicians in the other two groups
(p < 0.01), and the patients in this group had significantly
lower systolic blood pressure at 12 months (-4.6 mmHg;
95% CI -8.4 to -0.8).
The study by Jacobsen reached different conclusions,
although results should be interpreted with caution due to
the lack of adequate power for primary and secondary
analyses and the unique physician population in this
study. In this study, 164 medical residents at a university-
based general medicine clinic saw 368 patients who were
randomized to an experimental group (10-year CHD risk
scores plus a check list for physicians to indicate treatment
plans, placed on the front of patients' charts prior to visits)
or a control group (educational form conveying primary
prevention targets, placed on the front of patients' charts
prior to visits). The primary and secondary outcomes were
physicians' prescription of statin medications for lipid
lowering to high (10-year risk > 20%; encompassing 18%
of the patients in the study) and moderate risk patients
(10-year CHD risk 10–19%; encompassing 35% of
patients in the study). Other outcomes included physi-
cians' prescription of statins, hypertension medications,
aspirin, or lifestyle changes to patients at all levels of risk.
Investigators found no difference in prescription of statin
medications to high (+2%, p = 0.86) or moderate risk
patients (+10%, p = 0.18) by intervention assignment.
Changes in other outcomes were also non-significant
between groups, except for increased referrals (not coun-
seling) for smoking cessation (+13%, p < 0.01) and less
dietary counseling (-10%, p 0.01; but not referrals)Page 6 of 14
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from multiple testing.
The study by van Steenkiste and colleagues also failed to
find effects on prescribing, although results should be
interpreted in the context of their lower risk sample, their
target for prescribing (which was lifestyle changes that
would be appropriate for all patients regardless of risk
level), and moderate loss to follow-up, which diminished
the chance for physicians to make decisions based on glo-
bal CHD risk. In this study, 39 general practices (includ-
ing 45 interested physicians) were randomized to a 3-part
intervention (physician education, a paper-based decision
support tool to help physicians calculate global CVD risk
and explain it to their patients, and two scheduled medi-
cal consultations to encourage risk reduction) or a control
group (educational materials on the Dutch National Cho-
lesterol Guidelines). Physician level outcomes included
appropriate ordering of cholesterol testing for potentially
high risk patients (those with missing data for risk calcu-
lation, encompassing 59% of the study population), and
appropriate dietary and smoking advice for all patients
(including 19% who were high risk by Dutch National
Guidelines with CVD risk > 20% at 40 years, > 60% at 60
years, or diabetes). Patient level outcomes included
changes in risk perception, smoking, and physical activity
(but not diet) at 26 weeks. After adjustment for clustering,
there were no appreciable differences in physicians' die-
tary or smoking advice. There were also no changes in
patients' risk perception or self-reported smoking. Inter-
estingly, there were differences in patients' self-reported
physical activity at 26 weeks (+11%, p < 0.05); however, it
is not clear whether these were related to the intervention,
unaccounted for confounding with failed randomization,
or multiple testing.
Physician compliance with guidelines
One methodologically limited cross-sectional study by
Ramachandran [19] examined the effects of CHD risk cal-
culation on physician compliance with guidelines. In this
study, 68 randomly-selected general practitioners (GPs)
in the UK completed a postal survey in which they indi-
cated the need for lipid treatment in each of 20 case sce-
narios (mean 10-year CHD risk 28.9%). The primary
outcome was the proportion of correct responses based
on the UK lipid guidelines, which, at that time, recom-
mended lipid-lowering therapy for all patients with a 10-
year CHD risk > 30%. GPs were reminded of this guide-
line in the cover letter that accompanied the question-
naire. Unfortunately, design limitations, most notably the
small sample size and the response rate of only 30.5%,
seriously limit the study's primary conclusion that there
was no difference in the appropriateness of decision-mak-
ing between GPs who made recommendations after calcu-
lating CHD risk (N = 52) and those who made
recommendations without calculating risk (N = 26, P =
0.21).
Changes in CHD risk factors and global CHD risk
Three studies examined the effects of CHD risk calculation
on changes in risk factors and global CHD risk.
Two of these studies have been discussed in detail above.
As already noted, a fair quality cluster randomized trial by
Montgomery [20], showed that risk calculation using a
chart-based risk calculation system was associated with
lower mean systolic blood pressure at 12 months com-
pared to use of no risk calculation system in a high risk
population (86% of individuals at high risk). Risk calcu-
lation resulted in no difference in the proportion of indi-
viduals at high risk (CHD risk > 10%), however, perhaps
because of the high proportion of patients whose baseline
risk was significantly above the 10% threshold. A fair
quality cluster randomized trial by van Steenkiste [24], on
the other hand, showed mixed effects on CHD risk factors
(increased self reported physical activity (+11%, p < 0.05)
and unchanged self-reported smoking). This study, how-
ever, targeted lifestyle changes that would be appropriate
for all patients regardless of risk level, and was conducted
in a lower risk sample with moderate loss to follow-up
(diminishing the chance of physicians to make decisions
based on global CHD risk) and unaccounted for con-
founding.
A third study by Lowensteyn and colleagues [21] found
reductions in some (but not all) risk factors and in CHD
risk; however interpretation of these results is even more
difficult due to the study's methodological limitations. In
this study, 253 Canadian physicians recruited from a con-
tinuing medical education meeting on cardiovascular risk
assessment were randomized to receive either a computer-
ized risk report on their patients within 10 working days
of their patient's clinic visit (profile group) or no report
(control group). Two-week follow-up visits were sched-
uled for all patients in the profile group so that CHD risk
could be communicated to patients; subsequent follow-
up was at the discretion of the physician and patient. Risk
factor information was collected on control patients, but
no risk profile was provided until after the study period.
The authors hypothesized that assessing CHD risk at base-
line would encourage the 63% of patients who were at
high-risk in this study to be seen for follow-up and that
this would be associated with enhanced control of CHD
risk factors. Although the likelihood of follow-up for high
versus low risk persons was higher in the profile group
than the control group (difference 0.46, 95% CI 0.08 to
0.87), the differential follow-up rates at 3 months
between the two study arms (50% profile group; 25%
control), the low physician response rate, and the use of a
convenience sample of patients, all combine to hamperPage 7 of 14
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change, which suggested that patients in the profile group
had significantly greater reductions in lipid values and cal-
culated 8-yr CHD risk, but not in blood pressure or smok-
ing (see Additional file 2).
Changes in CHD events
We found no studies that addressed the effect of physician
knowledge of global CHD risk scores on changes in actual
CHD events.
The harms of CHD risk calculation
We found five studies examining the effects of patient
knowledge of CHD risk calculation on psychological out-
comes and health status (see Additional file 3). Quality
ranged from fair [27,28] to methodologically limited
[25,26,29].
Psychological outcomes
Four studies examined the effects of patient knowledge of
global CHD risk scores on psychological outcomes [26-
29]. Three of these studies examined effects on the Gen-
eral Health Questionnaire (GHQ-12 or 28). The GHQ is a
self-administered questionnaire that was designed and
validated to detect psychiatric disorders in non-psychiat-
ric settings [31,32], but has been widely used to capture
the harms of screening [33,34] given the face validity of
questions, which focus on anxiety, depression, hypochon-
dria, and social dysfunction. The fourth study examined
effects on overall satisfaction with life, measured by a sin-
gle item Likert scale with moderate correlation with the
GHQ.
In a prospective cohort study by Connelly [26], 5772 men
in 9 practices underwent CHD screening and were
informed of their level of CHD risk (low or higher than
average in 6 practices; and low, moderate, or high in 3
practices) via mailed communication. Men categorized as
"high" or "higher than average" risk (18.5%) were sched-
uled for a follow-up appointment to discuss their results
and were invited to participate in a clinical trial. Men cat-
egorized as "moderate" risk received general advice about
their risk factors with their mailing but no scheduled fol-
low-up visit. Men categorized as "low" risk simply
received the mailing stating they were at low risk. Psycho-
logical symptoms were assessed using the GHQ-28 at the
baseline, after the mailing, and at 3-month follow-up.
Results indicated that men who were labeled as being at
either "high," "higher than average," or "low" risk showed
a decrease in their psychological symptoms after labeling,
but men labeled as "moderate" risk had an increase in
psychological symptoms (see Additional file 3). The lack
of a scheduled follow-up appointment in the moderate
risk group may explain this result, although the lack of
reporting of baseline characteristics and substantial
patient attrition (~35%) make interpretation difficult.
Two fair quality studies by Christensen [27,28] support
the hypothesis that counseling and scheduled follow-up
may mitigate any potential adverse effects from knowl-
edge of CHD risk scores. In the first study [27], 52% of
2452 men randomly sampled from 2 municipalities in
one county in Denmark attended a health screening and
had their CHD risk calculated. Patients at all risk levels
had immediate counseling and those designated to be at
increased or high risk (n = 164) were scheduled a second
examination. All men at increased or high risk completed
a GHQ-12 at baseline and 6 months, as did a random
sample of men at low or moderate risk (n = 188). Investi-
gators found no differences in GHQ scores at 6 months
among men designated to have these different risk levels
(change in GHQ score -0.20, p 0.8). In the second study
by Christensen [28], a random sample of 1507 patients
from all 9 practices in one county in Denmark were ran-
domly assigned to receive one of two screening interven-
tions (e.g. health screening with written notification of
their global CHD risk from their provider plus either 1)
optional or 2) scheduled yearly follow-up) or no screen-
ing. Men who received scheduled follow-up helped set the
agenda for their visit and were invited to set a maximum
of three health-related lifestyle goals for the following
year, which were confirmed in writing [35]. Outcomes
were measured at 12 months and five years and showed
no differences between the intervention groups or the
intervention and control groups in changes in the GHQ-
12.
One final nested cross-sectional study by Meland [29] also
argues that scheduled follow-up may mitigate against any
potential adverse effects from knowledge of CHD risk
scores, although results must be interpreted with caution
given the high potential for confounding. In this study,
investigators compared the overall satisfaction with life of
115 high risk men enrolled in a randomized trial of heart
disease prevention (including every 3 month follow-up)
with the overall satisfaction with life of a random sample
of low risk men (n = 92, comprising 61% of those sent a
postal query) who were excluded from participation in
the trial. Baseline characteristics of participants were not
provided, but significant differences would be expected
based on risk alone. Satisfaction with life was measured
with a single question at screening and inclusion, which
showed moderate correlation to the GHQ-28, and was no
different in men who were labeled as high risk and
enrolled in the trial and those who were low risk and pre-
cluded from enrollment (between group difference +0.1
on a 7-pt Likert scale, p0.9).Page 8 of 14
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A single methodologically limited randomized controlled
trial by Marteau [25] examined the effects of patient
knowledge of CHD risk scores on perceived general health
status. In this study 3000 couples were randomized to
screening, including CHD risk calculation, or no screen-
ing. All patients who had a CHD risk calculated were
counseled on ways to reduce CHD risk, and they were
offered follow-up at a frequency commensurate with their
level of risk (i.e. more frequent follow-up for higher risk
patients). Outcomes included perceptions of health, the
risk of suffering a heart attack, and the ability to reduce
CHD risk at 1 year. Results suggest that participation in a
screening program including calculation of a CHD risk
score and appropriate counseling was not associated with
adverse concerns about health, although subjects who
were screened did have a sense of less ability to lower their
risk. Unfortunately, limited data about the baseline char-
acteristics of participants (even in background studies)
and patient follow-up with the possibility for confound-
ing limit conclusions from these findings.
Motivation
A single methodologically limited study by Marteau [25]
examined the effects of patient knowledge of risk scores
on motivation. This study was discussed in detail above.
As already noted, this study showed that subjects who par-
ticipated in a screening program that included calculation
of a CHD risk score has a reduced sense that they could
lower their risk (-6.4%, p < 0.001). Interestingly, this
lower self efficacy was associated with greater risk reduc-
tion, suggesting that the lower self efficacy may have
resulted from activated patients exhausting their options
for risk reduction or reaching personally acceptable levels
of risk. Unfortunately, authors did not have data to exam-
ine possible explanations further and methodological
issues hamper interpretation.
Discussion
Clinical guidelines have suggested that calculation of glo-
bal CHD risk is a useful addition to the clinician's arma-
mentarium to reduce the burden of CHD in the
population. However, we found surprisingly little evi-
dence that physician knowledge of global CHD risk cur-
rently translates into improved clinical outcomes. We
found two fair quality studies that showed that physician
knowledge of global CHD risk is associated with increased
prescription of cardiovascular drugs in high risk (but not
all) patients. Two additional fair quality studies showed
no effect on their primary outcomes, but one was under-
powered and the other focused on prescribing of lifestyle
changes, rather than drugs whose prescribing might be
expected to be targeted by risk level. One of these afore-
mentioned studies showed improved blood pressure in
high-risk patients, but no improvement in the proportion
of patients at high risk, perhaps due to the high propor-
tion of participants with baseline risks significantly
exceeding the risk threshold. Other studies were too meth-
odologically limited to draw conclusions regarding the
effect of physician knowledge of global CHD risk on ben-
eficial intermediate outcomes and no studies addressed
the effect of physician risk calculation on actual CHD out-
comes. Importantly, five studies (including two of fair
quality) examined harms and found no evidence of harm
from patient knowledge of global risk scores when they
were accompanied by counseling, or optional or sched-
uled follow-up.
The finding that physicians increased their prescribing of
cardiovascular drugs in high risk (but not all) patients sug-
gests that global CHD risk scores may be having their
intended effect: increasing allocation of therapies to those
most likely to benefit. Current guidelines recommend
aspirin and lipid lowering therapy for high risk patients;
and, evidence supports a similar approach for hyperten-
sion therapy [11,36]. By contrast, diabetes guidelines are
not risk-based because diabetes appears to be a CHD risk
equivalent [37]. Thus, the lack of effect of the intervention
on diabetes treatment in the Hall study could be seen, not
as a failure of global risk scores, but as a marker of good
clinical care. Similar reasoning might be applied to the
lack of diet, exercise, and smoking counseling in the stud-
ies by Hall, Jacobsen, and van Steenkiste [22-24]: these are
indicated regardless of CHD risk due to their efficacy in
preventing the development of either CHD risk factors or
other illness.
Despite increased prescribing of blood pressure and lipid
lowering drugs, the lack of effect of physician knowledge
of global risk scores on CHD risk in the Montgomery
study raises concerns about whether global risk scores will
ultimately translate into improved clinical outcomes.
Although the lack of effect may be due to measurement of
CHD risk as a categorical variable (> 10% or not), it may
also be due to a host of patient factors that are intermedi-
ary to improved clinical outcomes. To effect improved
outcomes, global risk scores must be communicated to
patients, increase their perceived risk, and increase their
acceptance and long-term adherence to prescribed ther-
apy. Almost none of these intermediate steps were meas-
ured in the studies in this review. Several studies have
examined the effect of giving global risk information
directly to patients (rather than physicians), however [38-
40]. In aggregate, these studies suggest that giving patients
global risk information in combination with individual-
ized counseling and/or detailed group education (but not
alone) may result in reductions in CHD risk factors (e.g.
poor diet, physical inactivity, obesity, and smoking) and
CHD risk. Unfortunately, none of these studies examined
the impact of global risk information on medication use,Page 9 of 14
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tion when compared with usual care [40].
To adequately judge the clinical impact of global risk
scores, more work is needed. Studies need to define a con-
ceptual framework for the impact of global risk calcula-
tion and more explicitly measure the potential mediators
of improved outcomes. This will allow a more accurate
assessment of whether risk scores have the potential to
effect changes in clinical outcomes. Risk is a difficult con-
cept, even for highly educated people [41]. Thus, future
studies need to be designed to identify whether physicians
and patients appropriately interpret and use risk scores or
whether changes in outcomes are due to the presentation
of ancillary information, particularly about risk factors
themselves.
Future studies also need to determine what happens when
physicians are asked to calculate risk (as they would in
clinical practice) rather than just interpret its meaning.
Montgomery's finding that patient risk factor profiles
improved when physicians were randomized to use a risk
chart, but not a computer-based intervention, raises ques-
tions about physicians' willingness to expend effort in cal-
culating global CHD risk. Through personal
communication, we learned that physicians in Mont-
gomery's study had computers available in all exam
rooms, but neither the actual use of the computer-based
intervention, nor the additional time and effort needed to
use it were measured. Future studies of risk calculation
interventions should measure both the use of the inter-
vention and environmental factors that are known to be
barriers to physician guideline adherence [42].
Future studies should additionally take care to address the
methodological challenges evident in studies included in
our review. Most importantly studies should address the
effects of clustering. Clustering can occur in two situa-
tions. First, it occurs when groups of individuals are rand-
omized and inferences are made about members of those
groups who are nested both within their group and their
study assignment. This nesting and the non-random sim-
ilarity of members within a group, if unaccounted for,
increases the likelihood that studies will draw falsely pos-
itive conclusions [43,44]. Three cluster randomized stud-
ies [20,21,24] in our review demonstrate this situation
and appropriately accounted for clustering. Second, in a
more subtle, but related, situation individuals are rand-
omized in a traditional randomized trial, but naturally fall
within a cluster (i.e patients are seen by a single physician)
that leads to similarity in behavior (i.e. individual physi-
cian practice pattern leads to similar outcomes among
patients) [43,44]. This situation, if unaccounted for, can
lead to falsely negative results. This situation occurred in
the study by Hall and colleagues [22], who didn't account
for clustering. This raises the possibility that there might
have been an effect of physician knowledge of global risk
scores among all patients (as well as high risk patients)
that might have been detected if they had accounted for
clustering. This situation also appeared to have occurred
in the study by Jacobsen [23], however, authors reported
in personal communication that they examined the effects
of clustering and they were minimal.
As the aforementioned design and methodological issues
are addressed, the clinical and research communities have
one additional important task: to define what ultimately
constitutes an acceptable measure of success in the use of
global risk scores. Although we found a lack of studies
examining the effect of global risk scores on actual CHD
events, we do not feel that future studies need to measure
the outcome of CHD events. Not only is the time and cost
necessary for this measure prohibitive, but previous
research has clearly established link between reductions in
CHD risk factors and CHD events [45,46]. We addition-
ally wonder whether global risk scores must be held to the
standard of measuring change in CHD risk factors or
actual CHD risk. Although risk scores would ideally
improve patient adherence, they may be considered suc-
cessful enough if they only increase acceptance of appro-
priate risk reducing therapies.
Observations aside, we must acknowledge the limits of
our own review. First, although a systematic literature
search was done, there remains the possibility that rele-
vant literature may not have been located. The questions
posed by this review lend themselves to a variety of
research designs by investigators in different fields, mak-
ing identification of relevant literature difficult. Addition-
ally, we searched only one database to identify literature
and excluded non-English language articles. Second,
although we used a quality assessment method that was
based on the best available evidence and has been used in
other similar reviews, there is the potential for misclassifi-
cation in quality because this measure has not previously
validated. We do not believe that these issues outweigh
the overall value of our work.
Conclusion
Our review provides preliminary evidence that physicians'
knowledge of global CHD risk scores may translate into
modestly increased prescribing of cardiovascular drugs
and modest short term reductions in CHD risk factors.
Whether these results are replicable, and translate across
other practice settings or into improved long-term CHD
outcomes remains to be seen. An important additional
area of study is whether risk scores cause unintentional
harm; limited available evidence suggests they don't when
accompanied by appropriate clinical support.Page 10 of 14
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